Hydrocortisone for Treatment of Mastitis in Non-Human Mammals, EP3829591A1
Summary
The European Patent Office published Patent Application EP3829591A1 for VIRBAC covering hydrocortisone formulations for treating mastitis in non-human mammals. The application names inventors HAVRILECK Bertrand, JASMIN Pierre, and MCGAHIE David with IPC classifications in A61K therapeutic preparations. The designated states cover EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.
What changed
The EPO published patent application EP3829591A1 for VIRBAC, covering hydrocortisone for treating mastitis in non-human mammals. Inventors include HAVRILECK, JASMIN, and MCGAHIE, with IPC classifications in pharmaceutical preparations (A61K). The patent is designated for all EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.
Veterinary pharmaceutical manufacturers and animal health companies developing mastitis treatments should monitor this application for potential freedom-to-operate implications. Patent publications do not impose compliance obligations but establish IP rights that may affect competitive product development.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HYDROCORTISONE FOR THE TREATMENT OF MASTITIS IN NON-HUMAN MAMMALS
Publication EP3829591A1 Kind: A1 Apr 08, 2026
Applicants
VIRBAC
Inventors
HAVRILECK, Bertrand, JASMIN, Pierre, MCGAHIE, David
IPC Classifications
A61K 31/573 20060101AFI20200207BHEP A61K 45/06 20060101ALI20200207BHEP A61P 27/00 20060101ALI20200207BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.